Chinese Hepatolgy ›› 2023, Vol. 28 ›› Issue (9): 1048-1049.

• Viral Hepatitis • Previous Articles     Next Articles

Clinical efficacy analysis of nucleoside (acid) analogues combined with polyethylene glycol interferon in the treatment of chronic hepatitis B

JIANG Zhao-rong, ZOU Mei, JI Teng-fei, LIU Huan, GU Sheng-wang, FENG Wei-guang, Zhao Wen-xi   

  1. Department of Infectious Diseases, Huai'an Medical District, General Hospital of the Eastern Theater Command, Jiangsu 223001,China
  • Received:2022-11-16 Online:2023-09-30 Published:2023-10-24
  • Contact: JIANG Zhao-rong,Email:1052489039@qq.com

PDF (PC)

107

Abstract: Objective To study the clinical cure effect of polyethylene glycol interferon α-2b in combination with nucleotide (acid) analog in the treatment of chronic hepatitis B.Methods Three hundred and ten patients with chronic hepatitis B enrolled during January 1, 2017 to June 30, 2022 were given polyethylene glycol interferon α-2b plus nucleoside (acid) analogue and set as the observation group. Another 310 patients previously treated with nucleotide (acid) analogue were taken as the control group. The HBsAg conversion rate, HBV DNA conversion rate and liver function regaining rate in both groups were compared. Results HBV DNA conversion, liver function regaining rate and HBsAg conversion rate in the observation group were 301 (97%), 278 (89.7%), 120 (38.7%), respectively, which were statistically significant different with those of 288 (92.98%), 243 (78.3%), 8 (2.58%) in the control group (χ2=262.091/161.895/167.293, all P<0.01). Conclusion The combination of polyethylene glycol interferon α -2b and nucleoside (acid) analogue is very effective in reducing the level of hepatitis B virus, and promoting liver function normalization in the treatment of chronic hepatitis B.

Key words: Polyethylene glycol, Nucleoside (acid) analogues, Chronic hepatitis B, HBsAg, Hepatitis B virus